IFHNOS 2026

Concurrent Session: Immunotherapy Abstracts

Scientific Session

Scientific Session

1:30 pm

27 August 2026

Mezzanine M4

Themes

Default

Chairs

Hamsu Kadriyan
Indonesia

Session Program

1:30 pm

Safety and Efficacy Findings From a Phase Ib/II Study of ASP-1929 Photoimmunotherapy (PIT) With Pembrolizumab (PEM) in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Anastasios Maniakas (Texas)

1:40 pm

A phase III randomized study of ASP-1929 photoimmunotherapy in combination with pembrolizumab (PEM) versus standard of care (SOC) in locoregional recurrent head and neck squamous cell carcinoma (rHNSCC)

Anastasios Maniakas (Texas)

1:50 pm

Neck Dissection and Immune Checkpoint Inhibitor Efficacy in Head and Neck Cancer – A Retrospective Study

Yoh-ichiro Iwasa (Nagano)

2:00 pm

Neoadjuvant Immunochemotherapy in T4b/N3 Locally Advanced Head and Neck Squamous Cell Carcinoma: Combined Analysis of Three Prospective Phase 2 Trials

Yiming Zhu (China)

2:10 pm

Development of Intra-Arterial Immunotherapy for the Head and Neck Cancer

Tetsuya Ogawa (Tokyo)

2:20 pm

A prospective study of definitive ChemoRadiation with ImmunOtherapy (CRIO) in locally or regionally advanced, unresectable cutaneous squamous cell carcinoma

Gary Ng (Queensland)

2:30 pm

The Rise of Neoadjuvant Chemoimmunotherapy: A Bilbliometric Analysis of Emerging Paradigms in Management of Locally Advanced HNSCC

Naomi Huang (Singapore)

2:40 pm

Predictive Value of PD-L1/PD-L2 Expression in Plasma Extracellular Vesicles for Neoadjuvant Immunochemotherapy of Head and Neck Squamous Cell Carcinoma: A Prospective Clinical Trial

Yudong Ning (Beijing)